CMPS vs. INDV, OCUL, CALT, AMPH, ARDX, DYN, AUPH, SNDX, BGM, and IOVA
Should you be buying COMPASS Pathways stock or one of its competitors? The main competitors of COMPASS Pathways include Indivior (INDV), Ocular Therapeutix (OCUL), Calliditas Therapeutics AB (publ) (CALT), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Dyne Therapeutics (DYN), Aurinia Pharmaceuticals (AUPH), Syndax Pharmaceuticals (SNDX), Qilian International Holding Group (BGM), and Iovance Biotherapeutics (IOVA). These companies are all part of the "pharmaceutical products" industry.
COMPASS Pathways vs.
COMPASS Pathways (NASDAQ:CMPS) and Indivior (NASDAQ:INDV) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, valuation and dividends.
COMPASS Pathways received 55 more outperform votes than Indivior when rated by MarketBeat users. However, 100.00% of users gave Indivior an outperform vote while only 81.48% of users gave COMPASS Pathways an outperform vote.
COMPASS Pathways has a net margin of 0.00% compared to Indivior's net margin of -3.96%. COMPASS Pathways' return on equity of -63.85% beat Indivior's return on equity.
46.2% of COMPASS Pathways shares are owned by institutional investors. Comparatively, 60.3% of Indivior shares are owned by institutional investors. 4.3% of COMPASS Pathways shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Indivior has higher revenue and earnings than COMPASS Pathways. Indivior is trading at a lower price-to-earnings ratio than COMPASS Pathways, indicating that it is currently the more affordable of the two stocks.
COMPASS Pathways has a beta of 2.34, suggesting that its share price is 134% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.
COMPASS Pathways currently has a consensus price target of $20.20, suggesting a potential upside of 407.54%. Indivior has a consensus price target of $15.00, suggesting a potential upside of 30.32%. Given COMPASS Pathways' higher possible upside, equities research analysts plainly believe COMPASS Pathways is more favorable than Indivior.
In the previous week, Indivior had 18 more articles in the media than COMPASS Pathways. MarketBeat recorded 26 mentions for Indivior and 8 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 1.31 beat Indivior's score of 0.92 indicating that COMPASS Pathways is being referred to more favorably in the media.
Summary
COMPASS Pathways and Indivior tied by winning 9 of the 18 factors compared between the two stocks.
Get COMPASS Pathways News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMPS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
COMPASS Pathways Competitors List
Related Companies and Tools
This page (NASDAQ:CMPS) was last updated on 5/1/2025 by MarketBeat.com Staff
Buy CMPS Stock Free CMPS Stock Alerts